Bispecific antibodies for the treatment of breast cancer.

ABSTRACT:

Introduction

There are more than two dozen bispecific antibodies (BsAbs) in development with a variety of designs which are relevant to breast cancer. The field of BsAbs for breast cancer includes agents that co-direct immune recognition of the cancer cell, target unique cancer antigens, and target the microenvironment. BsAbs are being developed for use as antibody-drug conjugates and as homing signals for engineered T-cells.

Areas covered

This review covers potential targets for bispecific antibodies, agents in pre-clinical development, agents in clinical trials, combinatorial therapies, and future directions.

Expert opinion

There is no BsAb approval expected for breast cancer in the near term, but late-stage trials are underway. Future BsAb roles in breast cancer ar

SUBMITTER: Dillon PM 

PROVIDER: S-EPMC8576064 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature